Lupus
ImmuPharma initiates phase 2/3 clinical trial for lupus treatment
June 19, 2023Research and Development Avion Pharmaceuticals, ImmuPharma, Immunology, Lupus, clinical trial
ImmuPharma has announced that it will commence a phase 2/3 adaptive clinical trial of P140 (Lupuzor) in patients with systemic …
GSK lupus treatment approved by European Commission
May 6, 2021GSK, Lupus, lupus treatment, pharma, pharma news
GSK’s Benlysta treatment, for patients with active lupus nephritis (LN) in addition to systemic lupus erythematosus (SLE), has been approved …
Immupharma and Avion sign agreement for lupus drug Lupuzor
November 29, 2019Medical Communications Diseases, Lupus, Lupuzor, avion
Immupharma has signed a development agreement with Avion Pharmaceuticals to acquire the licensing rights for Lupuzor, a peptide therapeutic and …
Expanded EU label for Benlyta now covers paediatric lupus patients
October 30, 2019Research and Development, Sales and Marketing Benlyta, Europe, GSK, Lupus, pharma
GlaxoSmithKline is celebrating the news that the European Commission has chosen to approve an expansion to the label of its …
Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome
October 28, 2019Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma
Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …
AstraZeneca lupus drug makes comeback to meet main goal at Phase 3
August 29, 2019Research and Development AstraZeneca, Lupus, anifrolumab, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint …
GSK’s Benlysta becomes first FDA-approved IV therapy for paediatric lupus
April 30, 2019Manufacturing and Production, Sales and Marketing Benlysta, FDA, GSK, Lupus, US, pharma
GSK has scored approval in the US with Benlysta (belimumab) for the treatment of systemic lupus erythematosus (SLE) in paediatric …
UCB and Biogen’s lupus drug falls short at Phase 2b
October 24, 2018Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …
AZ’s lupus drug fails to curb lupus activity at Phase 3
August 31, 2018Medical Communications, Research and Development AstraZeneca, Lupus, anifrolumab, pharma
AstraZeneca and its biologics R&D arm MedImmune have released a statement admitting that their fully human monoclonal antibody anifrolumab failed …
Interview: GSK’s subcutaneous formulation for Benlysta may help cut down hospital visits
June 22, 2016Research and Development Benlysta, EULAR, Interview, Lupus, NICE, autoimmune diseases, drug trial
UK drugmaker GlaxoSmithKine (LSE: GSK) reported positive results for Benlysta following a late-stage study at the annual European Congress of …
GSK ready for lupus drug push
November 12, 2015Manufacturing and Production, Research and Development, Sales and Marketing Benlysta, GSK, Lupus, SLE, belimumab, systemic lupus erythematosus
Having presented positive late-stage results for a new formulation of its inflammatory drug Benlysta, GSK says it will file supplementary …
AstraZeneca partners with PatientsLikeMe
April 14, 2015Sales and Marketing AstraZeneca, Lupus, PatientsLikeMe, Roche, diabetes, oncology, respiratory disease
AstraZeneca has signed a five-year agreement with PatientsLikeMe to give the pharma firm access to the latter’s global network of …
Research pact joins Pfizer and Merck Serono with academics
April 3, 2014Research and Development, Sales and Marketing Lupus, Merck Serono, Pfizer, broad institute, emd, kidney
Merck’s US affiliate EMD Serono and Pfizer have entered into a research agreement with the Broad Institute to investigate autoimmune …
Pfizer signs drug profiling deal with Nodality
August 10, 2012Research and Development, Sales and Marketing Lupus, Nodality, Pfizer, SCNP
Pfizer has signed a multi-year drug profiling deal with Nodality to help get the best from its autoimmune disease compounds. …
NICE no to GSK’s lupus drug Benlysta
April 27, 2012Sales and Marketing Andrew Dillon, Benlysta, GSK, Lupus, NICE
NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly. In its final …
Latest content
FibroFind appoints Lee Borthwick as CEO
